The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation.
 
Monzr M. Al Malki
Consulting or Advisory Role - CareDX; Gilead/Forty Seven; Incyte; NexImmune
Research Funding - Gilead/Forty Seven; Incyte; NexImmune; Stemline Therapeutics
 
Alla Keyzner
No Relationships to Disclose
 
Hyung C. Suh
Honoraria - Kite, a Gilead Company
Consulting or Advisory Role - Kite, a Gilead Company
 
Uday R. Popat
No Relationships to Disclose
 
Saar Gill
Employment - Boehringer Ingelheim (I)
Stock and Other Ownership Interests - Carisma Therapeutics; Interius Biotherapeutics
Honoraria - Amgen; Kite, a Gilead company
Consulting or Advisory Role - Asher Biotherapeutics; Carisma Therapeutics; Interius Biotherapeutics; Kite, a Gilead company; Mission Bio; Stelexis Therapeutics
Research Funding - Carisma Therapeutics (Inst); Interius Biotherapeutics; Interius Biotherapeutics; Novartis (Inst); Vor Biopharma
Patents, Royalties, Other Intellectual Property - Patents for chimeric antigen receptor T cells for acute myeloid leukemia; Patents on chimeric antigen receptor macrophages (Inst); Patents on genetic modification of hematopoietic stem cells (Inst)
 
Yi-Bin Albert Chen
Leadership - ImmunoFree
Stock and Other Ownership Interests - ImmunoFree
Consulting or Advisory Role - Alexion Pharmaceuticals; Astellas Pharma; Editas Medicine; Incyte; Magenta Therapeutics; Novo Nordisk; Pharmacosmos; Takeda; Vor Biopharma
 
Melhem M. Solh
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Seagen
Research Funding - Partner therapeutics
 
Lohith Gowda
No Relationships to Disclose
 
Erica Buonomo
Employment - TScan Therapeutics
Stock and Other Ownership Interests - TScan Therapeutics
 
Yun Wang
Employment - TScan Therapeutics
Stock and Other Ownership Interests - TScan Therapeutics
 
Jim Murray
Employment - TScan Therapeutics
Stock and Other Ownership Interests - TScan Therapeutics
Travel, Accommodations, Expenses - TScan Therapeutics
 
Gavin MacBeath
Employment - TScan Therapeutics
Stock and Other Ownership Interests - TScan Therapeutics
 
Debora Barton
Employment - Advanced Accelerator Applications; Carisma Therapeutics; Iovance Biotherapeutics; TScan Therapeutics
Leadership - Arovella Therapeutics
Stock and Other Ownership Interests - Advanced Accelerator Applications; Arovella Therapeutics; Carisma Therapeutics; Iovance Biotherapeutics; NKILT Therapeutics; TScan Therapeutics
 
Shrikanta Chattopadhyay
Employment - TScan Therapeutics
Stock and Other Ownership Interests - TScan Therapeutics
 
Ran Reshef
Consulting or Advisory Role - Allogene Therapeutics; Capstan Therapeutics; Gilead Sciences; Incyte; Orca Bio; Quell Biotherapeutics; Synthekine; TScan Therapeutics
Research Funding - Abbvie (Inst); Atara Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); CareDX (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); immatics (Inst); Incyte (Inst); Janssen (Inst); Precision Biosciences (Inst); Sanofi (Inst); Synthekine (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); TScan Therapeutics (Inst)
Expert Testimony - Bayer
Travel, Accommodations, Expenses - Gilead Sciences